Previous 10 | Next 10 |
Mushrooms seem to be popping up everywhere these days. All as millions digest the idea that mushrooms can support immune systems, reduce inflammation, and help improve moods. Chaga for example has even caught the attention to coffee drinkers, says Thrillist. " It's a superfood said to preve...
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance International IPO Index was down 3.4% year-to-date, while the ACWX was up 10.4%. For f...
MBPROJEKT_Maciej_Bledowski/iStock via Getty Images Advanced technology and cryptocurrencies might steal most of the spotlight on Wall Street, but a very old company had a very good day on Friday. Gunmaker Smith & Wesson (SWBI) rallied on news of a strong earnings report. Elsewhere, Sykes ...
Christian Angermayer, founder of atai Life Sciences (ATAI), said the firm's IPO will allow the firm to push its products through clinical trials, as it looks to create therapies based on psychedelic drugs like magic mushrooms and ayahuasca. This comes as the Peter Thiel-backed psychedelic psy...
Atai Life Sciences (Nasdaq: ATAI) announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. atai’s common shares are expected to begin trading on the Nasdaq Global ...
Psychedelic industry leader Atai Life Sciences B.V. (Nasdaq: ATAI) announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. atai’s common shares are expected to begin tradin...
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United ...
BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,00...
ATA (NASDAQ: ATAI ): Q3 GAAP EPS of -$0.07. Revenue of $5.9M Press Release More news on: ATA Creativity Global, Earnings news and commentary, Consumer stocks news, ,
BEIJING, Oct. 17, 2019 (GLOBE NEWSWIRE) -- ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG) , a company focused on providing students with quality educational experiences and services in China and abroad, today announced the Company’s founder,...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...